About Rigel
Rigel is a publicly listed company based in San Francisco (United States) founded in 1996. The company has 164 employees. Its chief executive, as recorded, is Raul Rodriguez. Rigel offers products and services including TAVALISSE, REZLIDHIA, and GAVRETO. Its focus areas include Life Sciences, Immunology, Drugs and Diversified. Its legal entity is Rigel Pharmaceuticals, Inc. Its competitors include Biogen, Moderna and Forge Biologics; 3 of its 3 listed competitors have raised funding.
Company details
Developer of drugs for hematologic disorders, cancer, and rare immune disease. The product TAVALISSE is the oral spleen tyrosine kinase inhibitor for the treatment of immune thrombocytopenia which is a rare autoimmune disease. Other candidates include Fostamatinib for covid-19, Bemcentenib for cancer, AZD0449 for asthma, R835, and R552 for immune disease.
- Annual Revenue$179.28 M (USD)53.38as on Dec 31, 2024
- Net Profit$17.48 M (USD)as on Dec 31, 2024
- EBITDA$26.42 M (USD)as on Dec 31, 2024
- Latest Funding Round$16.5M (USD), Grant
Jan 2021
- InvestorsMidCap Financial
& 1 more
- Employee Count164
Products & Services of Rigel
Rigel offers a comprehensive portfolio of products and services, including TAVALISSE, REZLIDHIA, and GAVRETO.
Treatment for immune thrombocytopenia and hematologic conditions.
Therapy targeting cancer through enzyme inhibition.
Drug for treating specific cancer types via targeted mechanisms.
Funding Insights of Rigel
- Total Rounds 2
- Last Round Grant — $16.5M
- First Round $60M
(Oct 2019)
- Investors Count 2
All 2 funding rounds of Rigel with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2021 | $16.5M | Grant | – | – | |
| Oct 2019 | $60M | Debt – Conventional | – | – |
2 investors in total: 2 institutional.
Investors in Rigel
Rigel has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include MidCap Financial and U.S. Department of Defense.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private debt funds are managed across multiple sectors. | 2008 | midcapfinancial.com | Bethesda, United States | |
Military forces are provided by the U.S. Department of Defense for national security. | defense.gov | Washington, D.C., United States |
Investor details for Rigel
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Rigel
57 people are tracked at Rigel (33 in leadership, 7 in board & advisors, 17 in team); the tracked headcount is 164.
| Name | Role | Group |
|---|---|---|
Raul Rodriguez | CEO & President | Leadership |
Kenny Corbett | Director Of Information Technology | Leadership |
Matthew McDonald | National Sales Director | Leadership |
Msn Lindsey Pangraze Aprn, Fnp-C | Medical Science Associate Director | Leadership |
Francois Ditrapani | Senior Vice President Medical Affairs | Leadership |
Matt Birrell | Executive Business Development Director | Leadership |
Dan Magilavy | Vice President Clinical Research | Leadership |
Jill Defratis-Robinson | Executive Director Of Clinical Operations | Leadership |
Strait Hicklin | Director Clinical Operations | Leadership |
Lisa Rojkjaer | EVP & Chief Medical Officer | Leadership |
Nathan Rustay | Sr Director, Medical Communications And Publications | Leadership |
Dean Schorno | EVP & CFO | Leadership |
Raul R. Rodriguez | President & CEO | Leadership |
Irina Kasatkina | Head Of Quality, Executive Director | Leadership |
Armand Llarena (Don) | Executive Director/head Of Accounting/finance | Leadership |
Elaine Vanderpoel-Barrios | Associate Director Of Accounting | Leadership |
Ralph Fuentes | Director Of SEC And Technical Accounting | Leadership |
Heather Beaudoin | Vice President Business Operations | Leadership |
Jennifer Setara Z. | Director, Legal And Corporate Counsel | Leadership |
Mike Morrow | Executive Director Of IT | Leadership |
37 more people are available in the full profile.
Complete people profiles for Rigel
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Rigel
Rigel is a publicly listed company on the NASDAQ with ticker symbol RIGL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date01 Dec 2000
- Listed onNASDAQ: RIGL
- Listed entityRigel Pharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINUS7665597024
- Share price$47.14 (-3.42% on the day) · 2026-10-13
- Market capitalisation$880.6M
- Price to earnings2.9
- EPS (diluted, trailing year)$16.32
- Volume (last session)133,999
Financials of Rigel
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $294.3M | $367.0M | $127.9M |
| 2024 | $179.3M | $17.5M | $26.4M |
| 2023 | $116.9M | -$25.1M | -$19.2M |
| 2022 | $120.2M | -$58.6M | -$53.2M |
| 2021 | $149.2M | -$17.9M | -$7.8M |
Detailed financial statements for Rigel
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Rigel
4 dated milestones of Rigel across 25 years, from founding to its latest funding, stage changes and deals.
- Founded Rigel is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $60.0M.
- Funding Latest funding round, Grant, of $16.5M.
Competitors of Rigel
Rigel has 3 listed competitors in our database, 3 of them funded. They include Biogen, Moderna and Forge Biologics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. |
Detailed competitors of Rigel
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Rigel
The website of Rigel (rigel.com) receives about 9.2K visits a month and ranks #2,021,438 among all websites worldwide, #2,753 in Biotechnology and Pharmaceuticals.
- Monthly visits9.2K
▼ 26.3% vs previous month
- Unique visitors5.6K
per month
- Global rank#2,021,438
among all websites
- Category rank#2,753
Health · Biotechnology and Pharmaceuticals
- Bounce rate47%
- Pages per visit1.5
- Average visit28 sec
- DevicesDesktop 28% · Mobile 72%
Websites whose visitors overlap most with Rigel. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| pfizer.com | 100% | 1.9M | #24,984 | View details | |
sanofi-aventis.us | sanofi-aventis.us | 100% | – | ||
| dynavax.com | 100% | 11K | #2,032,192 | View details | |
| merck.com | 100% | 656.8K | #78,842 | View details | |
| roche.com | 100% | 1.3M | #42,219 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 32 similar websites and full traffic analytics for Rigel
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 32 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Rigel (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Rigel
Complete news archive for Rigel
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rigel
Rigel was founded in 1996 and raised its 1st funding round 23 years after it was founded.
Rigel is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Raul Rodriguez is the CEO of Rigel, as recorded in our data.
Rigel has 164 employees.
Annual revenue of Rigel is $179.28M as on Dec 31, 2024.
Developer of drugs for hematologic disorders, cancer, and rare immune disease. The product TAVALISSE is the oral spleen tyrosine kinase inhibitor for the treatment of immune thrombocytopenia which is a rare autoimmune disease. Other candidates include Fostamatinib for covid-19, Bemcentenib for cancer, AZD0449 for asthma, R835, and R552 for immune disease.
Rigel's top competitors include Moderna, Forge Biologics and Biogen.
Rigel offers TAVALISSE, REZLIDHIA, and GAVRETO.
Yes, Rigel is publicly traded on NASDAQ under the ticker symbol RIGL.
Rigel has 2 investors. Key investors include MidCap Financial, and U.S. Department of Defense.
Rigel operates through Rigel Pharmaceuticals, Inc..